Brief: Arcutis Announces Positive Long-Term Results Of Roflumilast Cream
28/08/2024 13:04
Aug 28 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS ANNOUNCES POSITIVE LONG-TERM RESULTS OF
ROFLUMILAST
CREAM 0.05% SHOW DURABLE AND IMPROVED EFFICACY OVER TIME AND
FAVORABLE SAFETY PROFILE IN TREATMENT OF CHILDREN AGED 2 TO 5
WITH MILD TO MODERATE ATOPIC DERMATITIS
* ARCUTIS BIOTHERAPEUTICS INC: TO SUBMIT SNDA TO U.S. FDA IN
Q1
2025 FOR ROFLUMILAST CREAM 0.05%
* ARCUTIS BIOTHERAPEUTICS INC -LONG-TERM SAFETY AND
TOLERABILITY
PROFILE CONSISTENT WITH PIVOTAL DATA IN ATOPIC DERMATITIS (AD)
* ARCUTIS BIOTHERAPEUTICS INC -NO NEW SAFETY SIGNALS
OBSERVED
DURING 56 WEEKS OF TREATMENT
Source text for Eikon: ID:nGNX34752l
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf